Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction

Additional treatment options impact first-line treatment of mRCC: No

Current treatment options in mRCC

Discussion: Additional treatment options impact first-line treatment of mRCC

Additional treatment options impact first-line treatment of mRCC: Yes

What have we learned? Expert perspectives

From clinical trial to clinical practice: Evidence from the real world

The evolving treatment landscape for HER2-positive metastatic breast cancer

Navigating current treatment options for HER2-positive MBC: Patient journey 1

ecancermedicalscience editor's choice for September 2014

Benefits of investing in skin cancer prevention

Preventing skin cancer worldwide and the impact of different regulatory and economic priorities